GSK’s Blenrep Wins EU Approval for Advanced Multiple Myeloma Treatment

GSK’s Blenrep Gets EU Green Light for Advanced Multiple Myeloma

GSK’s antibody-drug conjugate Blenrep has received European Commission approval as a combination therapy for patients with relapsed/refractory multiple myeloma, marking a key step forward in cancer innovation.